Aerovate Therapeutics, Inc. financial data

Symbol
AVTE on Nasdaq
Industry
Pharmaceutical Preparations
Location
930 Winter Street, Suite M 500, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 824 % -13.3%
Debt-to-equity 13.9 % +17%
Return On Equity -81.4 % -32.1%
Return On Assets -71.5 % -29.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29M shares +4.03%
Common Stock, Shares, Outstanding 29M shares +4.4%
Entity Public Float 23M USD -90.1%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 28.6M shares +8.55%
Weighted Average Number of Shares Outstanding, Diluted 28.6M shares +8.55%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 53.2M USD -17.2%
General and Administrative Expense 21.4M USD +24.5%
Operating Income (Loss) -74.6M USD +8.37%
Nonoperating Income (Expense) 1.17M USD -35%
Net Income (Loss) Attributable to Parent -69.6M USD +7.8%
Earnings Per Share, Basic -2.44 USD/shares +15%
Earnings Per Share, Diluted -2.44 USD/shares +15%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33.8M USD +43.7%
Cash, Cash Equivalents, and Short-term Investments 78.6M USD -35.8%
Assets, Current 80.1M USD -35.5%
Property, Plant and Equipment, Net 6K USD -97.9%
Operating Lease, Right-of-Use Asset 209K USD -66%
Other Assets, Noncurrent 81K USD -96.4%
Assets 80.3M USD -37%
Accounts Payable, Current 224K USD -90.7%
Employee-related Liabilities, Current 2.87M USD -34.3%
Liabilities, Current 3.83M USD -78.3%
Operating Lease, Liability, Noncurrent 81K USD -77.4%
Liabilities 3.9M USD -78.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 105K USD -55.7%
Retained Earnings (Accumulated Deficit) -233M USD -42.6%
Stockholders' Equity Attributable to Parent 76.4M USD -30.2%
Liabilities and Equity 80.3M USD -37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.7M USD -107%
Net Cash Provided by (Used in) Financing Activities 471K USD +111%
Net Cash Provided by (Used in) Investing Activities 8.83M USD -42.6%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 29M shares +4.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.4M USD -444%
Deferred Tax Assets, Valuation Allowance 60.2M USD +38.1%
Deferred Tax Assets, Gross 60.2M USD +37.5%
Operating Lease, Liability 417K USD -38.2%
Depreciation 28K USD +33.3%
Payments to Acquire Property, Plant, and Equipment 16K USD -42.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -69.8M USD +6.76%
Lessee, Operating Lease, Liability, to be Paid 429K USD -39.4%
Operating Lease, Liability, Current 417K USD -0.71%
Lessee, Operating Lease, Liability, to be Paid, Year Two 242K USD -52.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 429K USD -7.94%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 12K USD -63.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 242K USD -50.5%
Deferred Tax Assets, Operating Loss Carryforwards 23.9M USD +47.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.16M USD +42.9%
Operating Lease, Payments 127K USD +3.25%
Additional Paid in Capital 309M USD +13.5%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 43K USD -79.1%
Share-based Payment Arrangement, Expense 11.3M USD -5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%